(NASDAQ: RCEL) Avita Medical's forecast annual revenue growth rate of 19.83% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.25%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.52%.
Avita Medical's revenue in 2026 is $75,630,000.On average, 6 Wall Street analysts forecast RCEL's revenue for 2026 to be $2,740,520,693, with the lowest RCEL revenue forecast at $2,606,514,665, and the highest RCEL revenue forecast at $2,857,640,663. On average, 6 Wall Street analysts forecast RCEL's revenue for 2027 to be $3,298,038,964, with the lowest RCEL revenue forecast at $2,988,399,372, and the highest RCEL revenue forecast at $3,656,481,121.
In 2028, RCEL is forecast to generate $4,065,024,770 in revenue, with the lowest revenue forecast at $3,888,432,473 and the highest revenue forecast at $4,215,019,978.